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ORIGINAL ARTICLE
Lamin B1 regulates somatic mutations and progression of
B-cell malignancies
T Klymenko1,6,7, J Bloehdorn2,6, J Bahlo3, S Robrecht3, G Akylzhanova1, K Cox4, S Estenfelder2, J Wang1, J Edelmann1, JC Strefford4,
TK Wojdacz4,5, K Fischer3, M Hallek3, S Stilgenbauer2, M Cragg4, J Gribben1 and A Braun1
Somatic hypermutation (SHM) is a pivotal process in adaptive immunity that occurs in the germinal centre and allows B cells to
change their primary DNA sequence and diversify their antigen receptors. Here, we report that genome binding of Lamin B1,
a component of the nuclear envelope involved in epigenetic chromatin regulation, is reduced during B-cell activation and
formation of lymphoid germinal centres. Chromatin immunoprecipitation-Seq analysis showed that kappa and heavy variable
immunoglobulin domains were released from the Lamin B1 suppressive environment when SHM was induced in B cells. RNA
interference-mediated reduction of Lamin B1 resulted in spontaneous SHM as well as kappa-light chain aberrant surface expression.
Finally, Lamin B1 expression level correlated with progression-free and overall survival in chronic lymphocytic leukaemia, and was
strongly involved in the transformation of follicular lymphoma. In summary, here we report that Lamin B1 is a negative epigenetic
regulator of SHM in normal B-cells and a mutational gatekeeper, suppressing the aberrant mutations that drive lymphoid
malignancy.
Leukemia advance online publication, 1 September 2017; doi:10.1038/leu.2017.255
INTRODUCTION
Class-switch recombination and somatic hypermutation (SHM) are
biological mechanisms through which B cells adapt and respond
to pathogens. These mechanisms involve a regulated process of
targeted mutation within the variable regions of immunoglobulin
genes, thus diversifying the antibody repertoire and allowing
afﬁnity maturation and isotype class switching. There is increasing
evidence that epigenetic factors, such as DNA methylation and
post-translational histone modiﬁcations, have major roles in
regulating class-switch recombination and SHM.1 In addition to
regulating expression of the central mutating enzyme activation-
induced cytidine deaminase (AID), these epigenetic factors (for
example, Spt6, H2BSer14p) also target the SHM/class-switch
recombination machinery, in a manner independent of V(D)J or
S region transcription, by inducing an open chromatin state and
recruiting critical adaptor proteins.24 Thus, B-cell SHM can be
regulated by a higher order of chromatin organisation.
From that perspective, it is intriguing that the subnuclear
position of chromatin domains (that is, proximity to the nuclear
envelope) has been suggested to impact both transcription and V
(D)J recombination.5 Furthermore, peripheral interphase relocali-
sation of immunoglobulin variable regions during both B-cell
development5 and antibody production in plasma cells,6 suggests
an in situ epigenetic mechanism by which sub-telomeric (IgHV) or
peri-centromeric (IgKV and IgLV) immunoglobulin variable loci can
transition from repressive to permissive chromatin states to
facilitate rearrangement.
The nuclear periphery, containing the IgH and IgK gene
clusters,5,7 is a unique compartment comprised of inner nuclear
membrane proteins and nuclear lamina.8 Previous genome-wide
and cytological studies revealed the regulatory role for some of
these nuclear proteins in higher level genome organisation and
gene regulation.9 In particular, lamina-associated domains (LADs)
were identiﬁed at the nuclear periphery using the DNA adenine
methyltransferase identiﬁcation (DamID) technique.10 Initial
reports described LADs as large (0.110 Mb), transcriptionally
silent, gene-poor domains associated with Lamin B1, comprising
of up to a quarter of nuclear chromatin.10 More recent studies
have also revealed an important role of LADs in the regulation of
gene expression and recombination.11,12 Moreover, developmen-
tally regulated genes were found to be speciﬁcally enriched in
these domains,13,14 leading to the theory that LADs are regulated
as facultative heterochromatin compartments during develop-
ment. In agreement with this, large-scale chromatin relaxation and
aberrant transcription were speciﬁcally linked to Lamin B1
depletion in senescent ﬁbroblasts and progeria cells.15,16 Further-
more, age-associated loss of Lamin B1 has been reported to lead
to systemic inﬂammation in Drosophila due to the derepression of
a large number of immune responsive genes.17 These data
strongly suggest the restrictive role of LADs in epigenetic gene
regulation. This restrictive inﬂuence can be transient and tightly
regulated depending on the cellular differentiation state.
Topologically, centromeric and telomeric chromosome regions
were the primary candidates for lamina-mediated epigenetic gene
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regulation as both were shown to colocalise with intra-nuclear
lamina structures resulting in their preferred peripheral
distribution.18,19
Given the apparent topological coincidence between LADs and
Ig variable clusters, we hypothesised that nuclear lamina might
have a paramount role in the dynamics of Ig-encoding variable
genome clusters. In particular, here we tested whether Lamin B1, a
principal LAD-associated component of the nuclear envelope, had
any restrictive role on SHM and the expression of Ig genes. Due to
the strong involvement of IgV mutations in the pathogenesis of
B-cell malignancies, we also tested whether nuclear lamina is
involved in the pathogenesis of germinal centre (GC) lymphomas
and chronic lymphocytic leukaemia (CLL). Finally, we have
elucidated associations of Lamin B1 expression with other
prognostic factors in CLL and its impact on the disease course
in a front-line clinical treatment trial (CLL8 study).
MATERIALS AND METHODS
Cell lines
Pfeiffer, Raji and SU-DHL4 cells were obtained from American Type Culture
Collection (ATCC). EHEB and Karpas422 cell lines were obtained from
European Collection of Authenticated Cell Cultures (ECACC, Public Health
England). BL2 cell line was obtained from the German Collection of
Microorganisms and Cell culture (ACC 625. Deutsche Sammlung von
Mikroorganismen und Zellkulturen, DSMZ). BL2 AID-/- cells were kindly
provided by Claude-Agnes Reynaud (INSERM U1151, Paris) and were
described previously.20 Cells were maintained in antibiotic-free RPMI 1640
medium with fetal calf serum (10%; Sigma-Aldrich, Gillingham, UK) and
glutamine (2 mM; Gibco, Invitrogen, Renfrew, UK) at 37 °C, 5% CO2, and
were routinely screened for mycoplasma contamination. Cytogenetically,
BL2 cells were characterised as human ﬂat-moded near-diploid karyotype
with 3% polyploidy; 4447o2n4XY, der(1)t(1;7)(q32;q11.2), der(6)t(1;6)
(q21;q25), t(8;22)(q24;q11.2), del(11)(q24.2); carrying t(8;22) effecting
juxtaposition of MYC with IGL@. Immunophenotypically, cells were
CD3− , CD10+, CD13, CD19+, CD20+, CD34− , CD37+, CD38+, cyCD79a+,
CD80+, CD138− , HLA-DR+, sm/cyIgG− , sm/cyIgM+, sm/cy kappa− , sm/cy
lambda+.
Induction and quantiﬁcation of SHM in the Ig V gene
In vitro SHM was induced as described20 with minor modiﬁcations. Cells
were incubated at 2 × 106 cells/ml in RPMI medium, containing 2.5 μg/ml
of biotinylated anti−human IgM (clone UCHB1 Caltag Laboratories,
Buckingham, UK), 10 ug/ml of anti-CD19 (clone RFB9, in-house, South-
ampton, UK) and 10 ug/ml of anti-CD21 (clone HB135, in-house, South-
ampton, UK) for 20 min at 4 °C. Cells were washed and then resuspended
in RPMI medium containing streptavidin-conjugated magnetic beads (5− 7
beads/cell) (Dynabeads M280, Thermo-Fisher, Renfrew, UK) and incubated
with agitation at 4 °C for 20 min. Complete RPMI medium containing 10%
FBS was added to the activated cells to a ﬁnal density of 1 × 106, followed
by incubation at 37 °C for 24, 48 or 72 h. To analyse Ig gene
hypermutation, the V4-39-JH5 gene was ampliﬁed from genomic DNA
with Pfu DNA polymerase (Thermo Scientiﬁc). The primers used were Vh4-
forward 5-TTCTTCCTCCTGCTGGTGGCG-3, Jh5 reverse 5-CTCCCCGGCTT
TCTTTCCTG-3. The conditions for PCR ampliﬁcation were 940 for 30 s, 600
for 30 s, 720 for 75 s, 25 cycles. The PCR products were then gel-puriﬁed
with a QIAquick gel extraction kit (Qiagen, Manchester, UK) and cloned
with the Zero Blunt TOPO PCR cloning kit (Thermo Fisher Scientiﬁc,
Renfrew, UK). Plasmid DNA extracted from individual bacterial colonies was
sequenced in an automated sequencer. Mutations per base pair were
calculated after aligning the V4-39-JH5 sequence from treated cells to the
reference sequence (Supplementary Figure 2) using DNASTAR's SeqMan
NGen software. At least 10 000 base pairs were assessed per experimental
condition.
Chromatin immunoprecipitation (ChIP)-sequencing analysis of
lamin B1 binding
ChIP was performed as described.16 BL2 cells were crosslinked with 1%
paraformaldehyde for 5 min at room temperature. Paraformaldehyde was
then quenched with glycine, and cells were harvested and sonicated using
Bioruptor Plus (Diagenode, Seraing, Belgium) 58 cycles 30 s active/30 s
inactive pulses to produce soluble ~ 300 bp chromatin fragments. Lamin
B1 and control IgG ChIP-Seq was performed on two independent
biological replicates with corresponding inputs per each condition (control
and SHM-induced), and then antibody-bound chromatin was immobilised
with anti-rabbit IgG-conjugated Dynabeads (112.04D, Invitrogen). DNA
libraries were prepared using Illumina Nextera DNA Library Preparation Kit
(FC-121-1030), and then massive parallel sequencing was performed using
Illumina HiSeq2500 sequencer, yielding ~ 70 mln to 90 mln raw reads per
sample.
Massively parallel sequencing and bioinformatical data analysis
Raw reads were mapped to the human genome (hg19) using the Bowtie 2
alignment software.21 Alignment BAM ﬁles were sorted by coordinates,
and PCR duplicates were removed using Picard's MarkDuplicates program.
To avoid any normalisation bias, each pair of aligned input and ChIP BAM
ﬁles were further processed to have the same read depth, using Picard's
DownsampleSam program on the larger of the two ﬁles. Lamin B1
enriched regions were deﬁned using the enriched domain detector
algorithm as described.22 The aligned peaks were then visualised using the
Interactive Genome Browser (IGV, Broad Institute, Cambridge,
Massachusetts).23 Complete ChIP-Seq data sets are available at Gene
Expression Omnibus (GEO) with accession number GSE89869.
LMNB1 RNA interference (RNAi) experiments
For LMNB1 RNAi transfections, 50 nM short interfering RNA (siRNA) was
electroporated into 106 of logarithmically growing BL2 cells using Lonza
Nucleofector 2b device (Basel, Switzerland), nucleofection solution T and
C009 programme. After electroporation, cells were resuspended and
immediately seeded into a pre-warmed fresh growth medium at 0.25 × 106
cells/ml concentration. Total and incorporated Lamin B1 levels were
assessed by WB or ImageStream cytometry 48 h after electroporation.
siRNAs used for this study: siGENOME siRNAs were received from
Dharmacon (GE Healthcare, Roserberg, Sweden) and target sequences
were the following: siRNA15-GAAGGAAUCUGAUCUUAAU-3, siRNA2
5-CAACUGACCUCAUCUGGAA-3, siRNA35-GAAAGAGUCUAGAGCAUGU
-3, 5-GCAUGAAACGCGCUUGGUA-3. ON-TARGETplus Non-targeting Con-
trol siRNA Pool (D-001810-10-05, Dharmacon) was used at 50 nM as an off-
target siRNA control.
Microscopy and image analysis
For immunoﬂuorescence microscopy, harvested cells were cytospun onto
poly-l-lysinecoated microscope slides (suspension cells) or mouse spleens
were cryosectioned using Leica CM3050 cryostat. Slides were ﬁxed in
20 °C methanol and then rinsed brieﬂy in ice-cold acetone. Slides were
washed in tris buffer saline (TBS)/0.05% Tween and then incubated with
appropriately diluted primary antibodies for 60120 min at room
temperature. The primary antibodies were diluted in TBS/0.1% bovine
serum albumin. Subsequently, slides were washed × 3 in TBS-Tween and
stained using the anti-rabbit Alexa Fluor 488, anti-mouse Alexa Fluor 594
or anti-rat Alexa Fluor 594 (all Abcam, Cambridge, UK). After three washes
in TBS/0.05% Tween-20, DNA was counterstained with propidium iodide or
4',6-Diamidino-2-Phenylindole, Dihydrochloride before mounting in Pro-
Long Gold Antifade Reagent (Invitrogen). Images were collected using a
Nikon Ci-L upright ﬂuorescence microscope and NIS elements software. In
situ ﬂuorescence intensity was measured within the linear ﬂuorescence
range, using MetaMorph software and integrated morphometry analysis
module.
Primary antibodies used for immunoﬂuorescence: rabbit anti-Lamin B1
(Abcam, ab16048), mouse anti-CD27 (BioLegend, London, UK, 356401), rat
anti-mouse IgD (Southern Biotech, Cambridge, UK, 1120-01), rat anti-
CD45R (B220) (Abcam, ab64100).
High-throughput image stream cytometry
For image stream cytometry, cells were ﬁxed in − 20 °C methanol, washed
× 3 in PBS and then non-speciﬁc binding was blocked using a 5 ml of PBS/
0.05% Tween/2% fetal calf serum. Cells were then stained rabbit anti-Lamin
B1 antibody (Abcam, ab16048) in PBS/Tween/2% fetal calf serum for
60 min. The concentration of primary antibody was calibrated to keep the
acquired ﬂuorescence within the linear dynamic range. After three washes,
cells were then stained with anti-rabbit Alexa Fluor 488, washed again, and
then DNA was counterstained with 4',6-Diamidino-2-Phenylindole, Dihy-
drochloride. High-throughput images were acquired using ImageStream X
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Mk II imaging cytometer, and Lamin B1 parameters were analysed using
Excel software.
Flow cytometry of plasma membrane surface immunoglobulins
To label cell surface immunoglobulins, cells were washed in PBS and
resuspended in PBS/5% fetal calf serum containing ﬂuorochrome-labelled
anti-Ig antibodies. After 1 h incubation, cells were washed in PBS, ﬁxed in
2% paraformaldehyde for 20 min, washed again and assessed by
FACScalibur analyser (BD Biosciences, Oxford, UK). Isotype and
ﬂuorochrome-matched non-targeting antibodies, added at equal concen-
trations, were used to set the background ﬂuorescence. The following
BioLegend (BioLegend UK, London, UK) antibodies were used in this study:
PE anti-human Ig light chain λ (316607), PE Mouse IgG2a, κ isotype Ctrl (FC)
(400213), PE anti-human Ig light chain κ antibody (316507), PE Mouse IgG1,
κ isotype Ctrl (FC) antibody (400113), FITC anti-human IgD antibody
(348205), FITC Mouse IgG2a, κ isotype Ctrl (FC) antibody (400209). FITC
Fab2 anti-human IgG (F0185), RPE Fab2 anti-human IgM (R5111), and
corresponding isotype controls (control reagent, Rabbit F(ab')2/FITC,
X0929, and control reagent, Rabbit F(ab')2/RPE, X0930) were obtained
from Dako (Agilent Technologies, Cheadle, UK).
Cell proliferation assay
Cell proliferation was assessed by FACS using Click-iT Plus EdU Flow
Cytometry or by ﬂuorescence microscopy using Click-iT EdU Alexa Fluor
488 Imaging Kits (Invitrogen/Thermo-Fisher, Paisley, UK). In all, 10 μM EdU
was added to growing cells for 2 (LMNB1 siRNA experiments) or 16
(assessment of steady-state proliferation) hours and then cells were
processed essentially according to the manufacturers protocols.
Western blotting
Whole-cell lysates were prepared in NuPage LDS sample buffer (Thermo-
Fisher), containing 0.1 M DTT. Samples were then separated by using
412% or 10% pre-cast NuPAGE Novex gels (Thermo-Fisher), and proteins
were transferred onto polyvinylidene diﬂuoride membrane using a wet
transfer system (BioRad, Hemel Hempstead, UK). Membranes were blocked
with 5% non-fat dried milk in TBS/0.05% Tween, incubated with the
appropriately diluted primary antibodies, washed, incubated with horse-
radish peroxidaseconjugated anti-rabbit, anti-mouse IgG (GE Healthcare/
Amersham, Little Chalfont, UK) or anti-rat (DAKO/Agilent, Stockport, UK),
and visualised by ECL (GE Healthcare/Amersham, Little Chalfont, UK) and
ChemiDoc imaging system (BioRad, Hemel Hempstead, UK). Primary
antibodies used for WB: rabbit anti-Lamin B1 (Abcam, ab16048), rabbit
anti-histone H3 (Abcam, ab1791), mouse anti-Bcl6 (Active Motif, 61194),
Rat anti-AID (Active Motif, 39886).
Animal immunisation
C57BL/6 mice were immunised by IP injection with 10 ng LPS plus 0.5 mg
ovalbumin (SIGMA) in 200 ul PBS. In all, 7 or 14 days later mice were killed,
spleens removed and processed for IHC/IF or the homogenised and the GC
B cells were isolated by MACS using a Mouse Germinal Center B Cell (PNA)
MicroBead Kit (Miltenyi Biotec, Bisley, UK). Animals were maintained in
local facilities and experiments approved by local ethical committees
under Home Ofﬁce license PPL30/2964.
Taqman quantitative reverse transcription PCR (qRT-PCR) gene
expression analysis
For cell line, genomic DNA and total RNA were puriﬁed using AllPrep DNA/
RNA mini kit (Qiagen) as per the manufacturers instructions. Total RNA
from primary B-cells isolated from mouse spleens was puriﬁed using
RNeasy mini kit. To remove DNA contaminations, all RNA samples were
treated on-column with the QIAGEN RNase-Free DNase; puriﬁed RNA was
quantiﬁed with Qubit RNA BR (Broad-Range) Assay Kit (Thermoﬁsher) and
reverse transcribed using High-Capacity RNA-to-cDNA Kit (Applied
Biosystems/Thermo Fisher Scientiﬁc, Renfrew, UK) according to the
manufacturers instructions. Triplicate ampliﬁcation reactions containing
1550 ng or input RNA each were carried out. TaqMan probes used in this
study are listed in Supplementary Table 1. mRNA encoding ribosomal
protein S18 and β-actin were used as the standard internal controls.
Reaction mixes (20 μl) contained TaqMan Gene Expression Master Mix 1 × ,
TagMan Gene Expression Assay 1 × and template cDNA. qPCR reactions
were performed and analysed on an Applied Biosystems ABI QuantStudio7
using ddCt comparison method. Graphing and statistical analyses were
performed using GraphPad Prism 7. All three groups were compared with
each other by one-way analysis of variance with Tukeys post-test.
Patients and samples
Expression proﬁling was conducted on peripheral blood samples from 337
previously untreated CLL patients. Samples were collected at enrolment on
the CLL8-trial, a prospective, international, multicenter trial comparing ﬁrst-
line treatment with FC or FCR in a 1:1 randomised fashion (www.
clinicaltrials.gov NCT00281918) as previously described.24 Ficoll density
gradient centrifugation for isolation of mononuclear cells followed by an
immunomagnetic tumor cell enrichment via CD19 (Midi MACS, Miltenyi
Biotec, Bergisch Gladbach, Germany) was performed on all samples. Data
on genomic aberrations (del(11)(q22.3), +12, del(13)(q14), del(17)(p13),
t(11;14)) the IGHV, TP53, SF3B1 and NOTCH1 mutational status was
assessed as previously described.24,25 Written informed consent and local
ethics committee approval was obtained in accordance with the
Declaration of Helsinki for all patients.
Gene expression proﬁling on BL2 cell line was conducted for two
independently cultured passages with four experimental approaches each,
with (1) control with non-targeting siRNA (2) control with non-targeting
siRNA and after induction of SHM (3) LMNB1 RNAi transfected (4) LMNB1
RNAi transfected and after induction of SHM. For siRNA-treated samples,
SMARTpool LMNB1 siRNA mixture of three siRNAs in equimolar
concentration was used.
RNA isolation and quality assessment
Total RNA for mRNA proﬁling was extracted from whole-cell lysates of
treated BL2 cells and primary patient samples according to the Allprep
DNA/RNA mini kit (Qiagen). Quality control was assessed using the Agilent
2100 Bioanalyser with the RNA 6000 Nano LabChip (Agilent Technologies).
The Chip was prepared according to the manufacturer's protocol and
analysed using the 2100 Expert software. To secure the best accuracy and
reproducibility samples with an RNA integrity number o7.0 were
excluded from further analysis. RNA for gene expression proﬁling on BL2
cell line functional studies had a RNA integrity number of 10.
Gene expression proﬁling on Exon ST 1.0 Arrays
Patient samples and samples from functional studies on BL2 cells were
analysed for mRNA expression using the Affymetrix GeneChip Human Exon
1.0 ST Array (Affymetrix, Santa Clara, CA, USA). The experiment was
conducted according to the manufacturers protocol. In brief, 250 ng RNA
per sample were ampliﬁed, transcribed to cDNA, fragmented and
subsequently labelled with Biotin. Array hybridisation was performed at
45 °C for 1618 h in the Affymetrix GeneChip Hybridisation Oven 640,
arrays were subsequently washed in the Fluidics Station 450 and scanned
on the GeneChip scanner 3000 7G. Complete GEP data sets are available at
Gene Expression Omnibus (GEO) with accession number GSE98529.
Normalisation and analysis of expression data
Statistical procedures were performed with the R software version 2.15.1
and BRB-ArrayTools Version: 4.2.1 Raw Affymetrix Human Exon array (HuEx-
1_0-st-v2) data ﬁles have been preprocessed by the robust multichip
average algorithm using either the implementation in the R-package
oligo26 or aroma.affymterix (University of California, Berkeley 2008). Besides
robust multichip average normalisation the default background correction
and quantile normalisation was applied. Aroma.affymterix was applied to
generate gene expression values summarised on the exon/probe set level
and on the transcript level using the core probe set deﬁnition according
to Affymetrix. Hierarchial clustering on selected genes was conducted
using the Genesis platform27 using pearson correlation and average
linkage as agglomeration rule and distance metric, respectively. Gene set
enrichment analysis28 was performed on C7: immunologic signatures
gene sets compiled at the Molecular Signatures Database, Broad Institute.
Statistical methods
Standard statistical means were used to evaluate associations between
clinical and molecular patient characteristics (χ2/Fishers exact; Mann
Whitney/KruskalWallis). Time-to-event parameters included progression-
free survival (PFS) and overall survival (OS), and were estimated by the
KaplanMeier method. Survival times were compared via two-sided
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non-stratiﬁed log-rank tests. Hazard ratios were calculated using Cox
proportional-hazard regression analyses. All tests were two-sided, and a P-
value o0.05 was deﬁned as statistically signiﬁcant. No adjustments for
multiple tests were performed. Statistical analyses were performed with
SPSS v23 (SPSS, Chicago, IL, USA).
RESULTS
To evaluate Lamin B1 dynamics in secondary lymphoid tissues, we
performed IHC staining for Lamin B1 in spleens of OVA-challenged
mice on day 14 post-immunisation, when the amount of GCs
per spleen was maximal (Figure 1a), accompanied by an average
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of sixfold increase in GL7+ splenocytes (Supplementary Figures 1A
and B). We observed a consistent reduction of nuclear Lamin
B1 within peanut-agglutinin (PNA) visualised GC cells but not
mantle zone B cells (Figures 1b and c) or follicular T cells (not
shown).
Complementary to spatial analysis of Lamin B1 in spleens of
OVA-immunised animals, we then MACS separated PNA+
splenocytes and performed qRT-PCR analysis of LMNB1 gene
expression in PNA+ vs PNA- fractions. Figure 1d demonstrate that
mRNA levels of LMNB1 were invariably decreased in PNA+
fraction. In contrast, expression of both mKI67 and TNFR6 were
elevated in PNA+ cells, consistent with their biological function in
activated murine B cells. Next, we tested whether reduction of
LMNB1 gene expression (Figure 1d) translates into a reduced
nuclear incorporation of Lamin B1 protein in PNA+ splenocytes.
Figures 1e and f, and Supplementary Figure 1C clearly demon-
strate that, as compared with PNA-depleted fraction, nuclear
Lamin B1 ﬂuorescence is signiﬁcantly decreased in PNA+ cells.
To test whether the decrease in Lamin B1 was a general cross-
species phenomenon related to GC formation, we next assessed a
panel of tissue microarrays containing 42 human biopsies with
previously diagnosed reactive lymphoid hyperplasia. Microscopic
studies, accompanied by image analysis revealed a consistent
decrease in nuclear Lamin B1 within the intrafollicular areas (as
assessed by Ki67 staining) of reactive lymph nodes, compared
with extrafollicular IgD+ mantle zone areas (Supplementary
Figures 1D and E). These results demonstrate a general decrease
in Lamin B1 during GC formation in humans and mice.
We next hypothesised that the observed decrease in GC Lamin
B1 might be associated with a speciﬁc change in GC B cells. After
antigen engagement, activation and several rounds of cell
division, B cells undergo SHM; a process by which the antibody-
encoding DNA sequences are mutated at a highly elevated
frequency, generating a diverse series of clones in the GC. We,
therefore, tested whether induction of SHM was associated with a
decrease in nuclear Lamin B1. For this purpose, we used BL2 cells,
a human B-cell line used previously as a model for assessing
SHM.20 Parallel assessment of Lamin B1 nuclear incorporation by
ImageStream and in situ cytometry revealed a robust reduction of
Lamin B1 at the nuclear periphery in cells undergoing SHM
(Figures 1g and h).
Keeping in mind the previously reported role of Lamin B1 in the
LAD-mediated epigenetic regulation of chromatin, we hypothe-
sised that Lamin B1 might be a mutational gatekeeper,
maintaining the IgH V gene clusters within the restrictive
facultative heterochromatic regions. Upon antigen stimulation,
these genome segments can be released from the suppressive
environment of the nuclear lamina, followed by access for
transcription and, potentially, mutations. In support of this
hypothesis, analysis of previous chromatin immunoprecipitation
(ChIP) studies performed in primary ﬁbroblasts15,16 revealed that
LADs precisely co-localise with all three (kappa, lambda, heavy) Ig
variable gene clusters (Supplementary Figure 2). This observation
suggests that IgV gene clusters can be prime candidates for
epigenetic regulation via LADs.
To address our hypothesis more directly, we next performed
ChIP-sequencing analysis of Lamin B1 genome binding in the
human BL2 cells undergoing SHM. Our analysis revealed that in
control cells the topology of Lamin B1 binding (deﬁned as LADs
according to our previously used algorithms29) precisely coincide
with the IgV clusters. Induction of SHM resulted in a rearrange-
ment of Lamin B1 binding to the genome with a general drop of
its binding to chromosomes 1 to 14 and increased binding to
smaller chromosomes 15 to 22 (Supplementary Figure 3A). On
that background, Lamin B1 canyonsareas of decreased
genome bindinginvariably coincided with IgV gene clusters,
even if surrounded by mesasareas of increased Lamin B1
binding after SHM induction (Supplementary Figure 3B).
Most importantly, results displayed in Figures 1i and j indicate
that, after stimulation, mutations in a 565 bp reporter fragment of
the V4-39-Jh5 gene increases ~ 4.5-fold (Figure 1i and
Supplementary Figure 4). Furthermore, 85% of nucleotide
substitutions are consistent with AICDA-dependent cytidine
deamination within the WRCY motif, a functional hallmark of
SHM (Supplementary Figure 4C). This increased mutational load
(Figure 1i) was accompanied by a gross threefold, yet precise
reduction of Lamin B1 binding to this fragment after SHM
induction (Figure 1j). These data suggest a direct involvement of
Lamin B1 in epigenetic regulation of SHM in IgV domains.
We next suggested that the decreased nuclear Lamin B1 could
be associated with altered cell cycle redistribution, which is a
function of the proliferative capacity of cells. According to this
hypothesis, cells that proliferate fast would have lower levels of
nuclear Lamin B1, which in turn would be consistent with a higher
proliferation rate of GC B cells in vivo, or activated BL2 or primary B
cells in vitro. To address this hypothesis directly, we compared
Lamin B1 levels within different cell cycle phases by FACS and
immunoﬂuorescence. Furthermore, we tested the correlation
between the proportion of EdU-positive cells and their Lamin B1
level in six different cell lines under various growth conditions
(Supplementary Figure 5). These experiments revealed no
association between steady state cell proliferation and nuclear
Figure 1. Nuclear Lamin B1 is reduced in follicular germinal centre B cells and is associated with somatic hypermutation. (a) C57BL/6 mice
were immunised with LPS plus ovalbumin (OVA), and 7 or 14 days later spleens were removed and processed for immunohistochemistry.
Figure represents the average number of GCs per spleen (n= 3)± s.e.m. (b, c) Spleen GCs were stained with anti-Lamin B1 antibodies
(AlexaFluor 488, green channel), Peanut Agglutinin (PNA) (Paciﬁc Blue, blue channel), and anti-B220 or anti-IgD antibodies (AlexaFluor 594, red
channel). Fluorescence intensity of the Lamin B1 channel (C, bottom image) was measured using MetaMorph image analysis software within
(PNA+ areas) or outside (B220+ or IgD+ PNA- areas) the GCs. At least 10 GCs from three spleens were analysed, and their Lamin B1
ﬂuorescence was compared with a similar number of randomly selected extra-GC areas of the same size. (d–f) C57BL/6 mice were immunised
with LPS plus ovalbumin (OVA), and after 14 days, spleens were removed, and PNA+ cells were isolated using PNA positive separation
MicroBead Kit. (d) Taqman qRT-PCR analysis showing relative LMNB1, TNFR6 and Mki67 mRNA level changes in PNA+ vs PNA- splenocytes.
(e) After microbead separation, nuclear Lamin B1 incorporation was measured by in situ cytometry in PNA+ vs PNA- cells (n= 3).
(f) Representative Lamin B1 immunoﬂuorescence (AlexaFluor 488, green) in PNA+ and PNA− cells in OVA immunised animals. Nuclei were
counterstained with DAPI (blue). (g) SHM was induced in BL2 cells according to the protocol (see Materials and Methods) and nuclear Lamin
B1 was assessed 48 h post induction by IF and ImageStream image cytometry. Total nuclear Lamin B1 levels were reduced by an average of
20%. (h) Line scan analysis by MetaMorph reveals an average 53% reduction in nuclear envelope bound Lamin B1 in SHM-induced cells, as
compared with control cell population. (g, h) are the representative images of ﬁve independent experiments. (i) DNA from control or activated
BL2 cells was isolated, cloned and then analysed for mutations within the IGHV4-39 gene as described in Materials and Methods. The reference
IGHV4-39 sequence and nucleotide substitution pattern after SHM induction and LMNB1 RNAi are displayed in Supplementary Figure 5.
At least 10 000 base pairs (bp) were analysed per condition, and the mutational load was expressed as mutations per bp. n= 4, ± s.e.m.
Po0.01. (j) ChIP-Seq analysis of the dynamics of Lamin B1 binding to the IGHV4-39 gene following SHM induction. As compared with control
cells, Lamin B1 binding to this gene was signiﬁcantly reduced 48 h after cell activation. BLAT alignment represents the IGHV4-39 sequence
where SHM was assessed by Sanger sequencing and clonal analysis. DAPI, 4',6-Diamidino-2-Phenylindole, Dihydrochloride.
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Lamin B1 (Supplementary Figure 5). In fact, more rapidly
proliferating cells had a tendency to increase their Lamin B1
incorporation (Supplementary Figure 5A) due to the marginally
higher amount of Lamin B1 in G2, as compared with G1 cells
(Supplementary Figures 5B and C). Likewise, in situ cytometry
showed no difference in Lamin B1 incorporation between EdU-
positive and EdU-negative cells (Supplementary Figures 6D and E).
These results suggest that a decreased Lamin B1 in GC B cells is
likely to be associated with a more speciﬁc role, which is not a
passive reﬂection of cellular proliferation per se.
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To test the impact of Lamin B1 on cell dynamics and SHM
directly, we then transfected BL2 cells with siRNA-targeting mRNA
transcripts from three different exons of the LMNB1 gene (See
Materials and Methods). In general, 5080% reduction of Lamin B1
protein level (Figure 2a) 48 h after siRNA electroporation
translated to an average of 32% reduction in Lamin B1 nuclear
incorporation (Figures 2b and c). Interestingly, this level of
reduced Lamin B1 incorporation was very similar to that produced
by SHM induction (compare Figures 1g and 2c), potentially
suggesting a functional epigenetic compartment of nuclear Lamin
B1 different from its structural function.
Having established a speciﬁc RNAi-mediated reduction of
nuclear Lamin B1, we next tested whether Lamin B1low cells
would exhibit any phenotypic features characteristic of GC B cells.
Our ﬁndings displayed on Figures 2d and e demonstrate that
proliferation boost, as detected by on average 27% more EdU-
positive cells, was a characteristic feature of siRNA-treated Lamin
B1low cells. This proliferation boost was accompanied by a general
upregulation of positive cell cycle regulatory genes which, in turn,
occurred alongside an upregulation of genes responsible for cell
cycle checkpoint execution or cell cycle arrest, and were speciﬁc
for LMNB1 reduction; independent of SHM induction (Figure 2f
and Supplementary Figure 6). We believe the latter can be
interpreted as a secondary cellular response to uncontrolled
proliferation and DNA lesions.
AICDA is a master regulator of antibody diversiﬁcation at DNA
level via SHM and class-switch recombination.30 AID expression
peaks in GCs where it is positively regulated by BCL6 via an
indirect miR-155-mediated mechanism.31 We set out to examine
that upregulation of AID might be a primary mechanism for SHM
induction by antigen ligation or LMNB1 siRNA. Figure 2g shows
that neither AICDA nor its GC regulator BCL6 is induced by
antibodies or LMNB1 siRNA. We, therefore, suggest that Lamin B1-
mediated chromatin accessibility could be the primary factor
regulating SHM in BL2 cells.
It is suggested that individual B-cells in lymphoid tissues
possess either kappa or lambda light chains. A mixture of kappa
and lambda-positive cells is characteristic of reactive or otherwise
benign GCs. Our previous immunophenotypic analysis of BL2 cells
revealed strong lambda chain expression on the cell surface,
which is likely to be due to BL2-speciﬁc t8,22 translocation
involving IGL@ locus. On the contrary, the non-rearranged
kappa-light chain, expressed from chromosome 2, was largely
absent from the cell surface. Consistent with our model, we found
that IGK@ was heavily incorporated within the Lamin B1-binding
sites. We next hypothesised that siRNA-mediated reduction of
Lamin B1 incorporation would release the IGK@ locus from its
suppressive environment that would result in de novo expression
of kappa-light chain on the cell surface. In agreement with this
hypothesis, decreasing Lamin B1 binding to the IGK@ locus
(Supplementary Figure 3B) was accompanied by ~ 5-fold induc-
tion of kappa light chain expression on the cell surface (Figure 2h).
Finally, we tested whether siRNA-mediated reduction of Lamin
B1 incorporation results in spontaneous SHM. By analogy with
Figure 1i, clonal analysis of the IGHV4-39 locus revealed a ~ 4-fold
induction of spontaneous SHM in cells treated with smartpooled
LMNB1 siRNA (Figure 2i) with 72.4% of nucleotide substitutions
falling within the AICDA-related mutational hotspots
(Supplementary Figure 4D). Notably, combining LMNB1 siRNA
treatment and induction of SHM by ligating surface antigens did
not alter the SHM rate induced by siRNA-treatment alone. This
suggests a shared cellular mechanism of SHM induction between
nuclear lamina and external stimuli, resulting in a binary induction
of SHM.
To further our functional evidence on the involvement of Lamin
B1 in SHM, we next tested whether IGHV4-39 mutations occurring
after LMNB1 RNAi treatment are AICDA dependent. To do this, we
did similar LMNB1 RNAi treatments in AICDA-/- cells described
previously.20 Figure 2j demonstrates that AICDA-/- background
almost completely negates both background and LMNB1 RNAi-
induced mutations. Interestingly, although we couldnot detect
any AICDA signal by qRT-PCR and western blotting (Figures 2k and
l), signiﬁcant amount of AICDA expression could be observed in wt
BL2 cells, which is in agreement with previously published
reports.20,32 Furthermore, its expression did not signiﬁcantly
change after LMNB1 RNAi (Figure 2k) that, in combination with
Figure 2g, suggests that other chromatin factors are at least as
important in SHM as AICDA expression per se. Out data suggest
that lamina-mediated conformational changes could be one of
these factors.
We were unable to establish a stable LMNB1-negative cell line
using CRISPR/CAS9 or short hairpin RNA approach. Neither are we
aware of the existence of any such human cell models, outside of
cellular senescence.
Formation of plasma or memory cells is the outcome for B cells
following SHM and clonal selection.33 Given the acute functional
impact of Lamin B1 in our in vitro system, we tested whether the
drop in Lamin B1 in GC B cells translates into their ultimate
differentiated state. If the GC-associated drop in Lamin B1 is
transient, this might then suggest a temporary chromatin access
Figure 2. RNAi-mediated reduction of nuclear Lamin B1 results in acute proliferation boost, de-novo surface antigen expression and AICDA-
dependent somatic mutations. (a) Three different LMNB1 mRNA-targeting siRNAs were nucleofected into BL2 cells and then total Lamin B1
protein level was assessed by western blotting 48 h post electroporation. (b, c) High throughput Lamin B1 nuclear incorporation was assessed
by ImageStream cytometry 48 h after siRNA treatment. At least 8000 cells were analysed per sample. Nuclei were counterstained with DAPI.
(b) Representative cells showing Lamin B1 ﬂuorescence within the median of sample intensity distributions. (c) Histograms showing absolute
value distributions for non-targeting siRNA control (NTC) or LMNB1 siRNA-treated cells. (d, e) EdU was added to WT, NTC or siRNA-treated cells
72 h post siRNA treatment for 2 h and then the proportion of EdU+ cells was assessed by FACS. (d) Representative EdU FACS proﬁle showing
33% proliferation boost in siRNA2, as compared with NTC-treated cells. (e) The average percentage of EdU+ cells from three independent
experiments± s.e.m. Po0.02. (f) Expression proﬁles of cell cycle regulatory genes in SHM-induced and/or LMNB1 siRNA-treated BL2 cells.
(NTC: control with non-targeting siRNA; NTC SHM: control with non-targeting siRNA and after induction of SHM; LMNB1: LMNB1 RNAi
transfected; LMNB1 SHM: LMNB1 RNAi transfected and after induction of SHM. Experiments were conducted in two independent BL2 cell
passages indicated with ‘-1’ and ‘-2’ behind the experiment label. For siRNA-treated samples, a SMARTpool LMNB1 siRNA mixture of three
siRNAs (a–f), in equimolar concentration was used. (g) Western blot analysis of AID and BCL6 proteins in antibody- or LMNB1 siRNA-treated
samples at 72-hour time point. Histone H3 was used as a loading control. (h) FACS analysis of Ig surface antigen expression. Surface IgG, IgM,
IgD, as well as kappa and lambda-light chain expression was assessed 72 h after cells were treated with NTC or SMARTpool LMNB1 siRNA. For
FACS, a ﬂuorophore and isotype-matched non-targeting antibody was used to set background ﬂuorescence. A representative of three
independent experiments. (i–l) Mutations targeted to V4-39-Jh5 fragment are AICDA dependent. (i) Cells were treated with SMART pool
LMNB1 siRNA and then mutations were assessed by Sanger sequencing 72 h post transfection. For combined antibody/siRNA-treated
samples, SHM was induced 48 h after LMNB1 siRNA transfection, and then DNA was isolated 72 h after initial treatment. (j) Parental and AID-
deﬁcient BL2-clones were treated with LMNB1 RNAi and mutations induced in V4-39-Jh5 gene were analysed. *Po0.05, **Po0.01. (k) qPCR
and (l) western-blot analysis of AICDA expression in BL2 wt and AID-/- cells treated with non-target control (NTC) or LMNB1 siRNA. Data
represents the average of three experiments± s.e.m. Po0.01.
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for a naive B cell to rearrange its Ig domains and, hence, ﬁne-tune
the antibody repertoire. To address this question, we ﬁrst
compared the expression of Lamin B1 in human CD27+ vs
CD27− B cells within the GCs of fresh frozen human lymph nodes.
CD27 is a widely accepted marker of memory B cells that can be
detected in human GCs34 before GC-dependent memory cells
relocate to the marginal zone.35,36 Figures 3ac demonstrates that
CD27+ cells have a substantially higher expression of Lamin B1
compared with CD27− GC B cells. These data suggest that the
drop in Lamin B1 is transient and is only temporally associated
with SHM in normal B cells.
Although the cellular origin of CLL is still debated, several lines
of evidence suggest that CLL cells are antigen-experienced,37
resembling memory B cells.38 Within this context, IGHV-mutated
CLL cells, associated with favourable clinical prognosis and
derived from the CD5+/CD27+ post-GC B-cell subset, could be
similar to classic memory B cells generated by a typical GC-based
reaction, represented in our system as a CD27+ GC B cells
(Figures 3ac).
By analogy with the normal CD27+ memory B cells, we
hypothesised that IGHV-mutated CLL (mCLL) would be associated
with higher Lamin B1 expression levels as compared with
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Figure 3. Nuclear Lamin B1 levels are restored in memory B cells and low LMNB1 expression level is an adverse prognostic factor in CLL.
(a) Fresh frozen normal human lymph nodes were ﬁxed in −20 °C methanol and then stained with PNA (blue), Lamin B1 (green) and anti-
CD27 antibodies (red). (b) A zoomed in the area of (A, square) representing differential Lamin B1 expression in CD27+ vs CD27- cell. (c) High-
throughput comparison of Lamin B1 levels in CD27+ and CD27- GC cells. Lymph nodes from three patients were assessed and in total 50
randomly selected CD27+, and 50 randomly selected CD27- GC cells were analysed using MetaMorph software. (d, e) showing Kaplan–Meier
estimates of progression-free (PFS) (d) and overall (OS) (e) of CLL patients enrolled on the CLL8-trial as a factor of LMNB1 expression,
dichotomised by the median (46.51, N= 168 and ⩽ 6.51, N= 169. (f) Univariate Cox regression analysis comparing low (⩽6.51, N= 169) and
high (46.51, N= 168) LMNB1 expressing CLL patients as a factor of the treatment regime (FC or FCR) applied. *Po0.05, **Po0.01,
***Po0.001.
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unmutated CLL cases (uCLL). Furthermore, given an association of
IGHV mutational status with clinical outcome, we anticipated that
Lamin B1 would per se constitute a prognostic factor in CLL.
With that in mind, we analysed gene expression proﬁles of 337
previously untreated CLL patients, enrolled on the CLL8 trial
evaluating FC versus FCR in a randomised fashion (NCT00281918)
(refs 24,39). As implicated from our functional studies, higher
LMNB1 expression, as dichotomised at the median (LMNB1
low⩽ 6.51 vs LMNB1 high46.51), was inversely correlated with
high-risk genomic aberrations (Supplementary Table 2) and was
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Figure 4. Nuclear Lamin B1 decreased in B-cell lymphomas. (a) Immunohistochemical tissue microarray analysis of nuclear Lamin B1 in tissue
biopsies of B-cell malignancies showing decreasing LMNB1 staining with increasing aggressiveness. (b) Representative IHC images from the
lymphoid tumour panel displayed in a. The horizontal line represents Lamin B1 immunoreactivity within the intrafollicular areas of benign
reactive lymph nodes. At least three samples were analysed per tumour type, and bars represent average H-score values± s.e.m. (c) Lamin B1
immunoreactivity in sequential biopsies from a FL patient (upper image) that later underwent FL transformation (lower image). (d) Lamin B1
H-score values of 43 FL biopsies and their transformed counterparts. Each line connects two sequential biopsies from the same patient. (e) Lamin
B1 dynamics within the context of B-cell natural development in secondary lymphoid organs. Upon antigen stimulation in secondary lymphoid
organs, mature naive B cells undergo activation accompanied by a series of complex processes including SHM and clonal expansion. Our data
suggest that speciﬁc reduction of nuclear Lamin B1 in GC B cells is instrumental for these processes. Furthermore, our observations suggest that
this low level of Lamin B1 is locked in B cell malignancies arising from a corresponding B-cell development stage.
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associated with shorter median PFS (32.4 vs 49.9 months,
P= 0.010) and, notably, OS (83.6 months vs not reached,
P= 0.001) and (Figures 3d and e).
Conversely, we were unable to detect a similar clinical impact
for LMNB2 and LMNA genes (Supplementary Figure 7), encoding
two other components of the nuclear lamina, Lamin B2 and Lamin
A/C, respectively. The latter highlights a highly speciﬁc impact of
Lamin B1 in the molecular pathology of CLL.
Moreover, univariate Cox regression analysis comparing low
(⩽ 6.51) and high (4 6.51) LMNB1 expression cohorts revealed an
overall hazard ratio of 0.715 for PFS and 0.551 for OS (95%
conﬁdence interval) (Figure 3f), suggesting a strong protective
impact of LMNB1 expression in CLL. Interestingly, further
stratiﬁcation of patients according to their treatment regime
revealed a very similar LMNB1-related hazard ratio regardless of
the therapeutic modality applied (Figure 3f). The latter suggests
that the molecular mechanisms responsible LMNB1-mediated
protection of CLL patients are different from the mechanisms
covered by chemotherapy.
Further, we were able to solidify functional model-derived
clinico-biologic implications in the context of CLL. First, we
correlated LMNB1 expression from our data sets with the total
amount of Lamin B1 protein, and, although not absolute, a
positive correlation between gene expression and protein content
could be observed (Supplementary Figure 8A). Next, when
performing gene set enrichment analysis for CLL cases dichot-
omised for lower and upper quartiles of LMNB1 expression, we
found LMNB1 quartile low cases to extensively match signatures
of anti-IgM-activated B cells (Supplementary Figure 8B) while
there was only a 1.12-fold expression change for AID observable
for LMNB1 quartile low expressing CLLs (data not shown). This
suggests that CLL cells with LMNB1 downregulation are tran-
scriptionally locked in an activated state. Complementary to this,
and resembling LMNB1 siRNA phenotype in BL2 cells, we found an
inverse relationship between expression of LMNB1 and expression
of positive cell cycle regulatory genes (Supplementary Figure 8B).
On that background, low LMNB1 expression was also strongly
associated with high BCL2 and low CDKN1A expression levels
(Supplementary Figure 8B), further highlighting similarities
between Lamin B1low and GC B cells.
We next assessed whether differential expression of LMNB1
in CLL can be attributed to differential CpG methylation within
this gene. Given a strong association of LMNB1 expression
with IGHV mutational status, we next compared the methylation
values (normalised Inﬁnium HumanMethylation450 BeadChip
beta values) for LMNB1 promoter CpG sites between CLL patients
with mutated and non-mutated IGHV. Two sample t-test
with equal variances revealed no association between LMNB1
methylation and IGHV mutational status, suggesting that
mechanisms other than CpG methylation are responsible
for regulating LMNB1 expression in CLL (Supplementary
Figure 9).
We next hypothesised that a permissive chromatin state,
associated with decreased nuclear Lamin B1 in GC B cells, might
be linked to secondary off target mutation events. The latter can
be followed by a formation of malignancies that originate in the
GC such as follicular lymphoma (FL) or diffuse large B-cell
lymphoma. In support of this hypothesis, we found a consistently
decreased amount of Lamin B1 in the majority of primary
lymphoid tumours, as compared with intrafollicular areas of
normal human reactive lymph nodes (Figures 4a and b).
Intriguingly, we found decreased Lamin B1 in other non-
lymphoid malignancies including acute myeloid leukaemia
demonstrating that LADs are also deregulated in other haemato-
logical malignancies (Figure 4a). Next, we assessed a chronological
series of biopsies from 43 patients with FL, which subsequently
underwent transformation. We found that FL transformation was
strongly associated with a further decrease in Lamin B1 (Figures 4c
and d), suggesting a possible involvement of LADs in the
progression of this malignancy.
DISCUSSION
One of the principal questions in B-cell biology yet to be answered
is how SHM machinery accesses immunoglobulin loci. For SHM to
take place, Ig variable loci should be subjected to AID-mediated
deamination as well as DNA cleavage and repair. Each of these
events is likely to be regulated by speciﬁc changes in chromatin,
resulting in its open and accessible conformation. In resting B
cells, most of the IgH locus exist in a closed chromatin state,
enriched in repressive histone marks, such as H3K9Me3 and
H3K27Me3,40 as well as HP1-γ protein.41 Within that context, it is
intriguing that both H3K9Me3 and HP1-γ are known to be
associated with Lamin B1,42 topologically deﬁning lamina-
associated chromatin domains.10,16
In this study, we show that perinuclear Lamin B1 is decreased in
GCs of mouse and human lymphoid follicles. The reduction of
nuclear Lamin B1 could also be observed after induction of SHM
in vitro. This was accompanied by the reduced genome binding of
Lamin B1, including the domains that encode variable immuno-
globulin parts. Furthermore, the clonal analysis revealed that the
rate of SHM was grossly increased when Lamin B1 genome
incorporation was suppressed by RNA interference, providing for
the ﬁrst time a direct functional link between SHM and structural
components of the nuclear envelope. Downstream of GC, we
found that Lamin B1 levels were restored in CD27+ memory B cells
indicating the temporary nature of Lamin B1 decrease in activated
B cells. This suggests an epigenetic window of opportunity for a
GC B cell to start and complete SHM when the chromatin state is
permissive.
Interestingly, Lamin B1 dynamics in GC/post-GC B cells
translates into CLL, which is a post-GC malignancy. In particular,
IGHV-mutated CLL cells, associated with a favourable clinical
prognosis and derived from the CD5+/CD27+ post-GC B-cell
subset43 displayed signiﬁcantly higher LMNB1 gene expression as
compared with uCLL samples. Furthermore, low LMNB1 expression
was strongly associated with multiple cytogenetic abnormalities
and was a strong-negative prognostic factor for both PFS and OS.
The strong direct relationship between the LMNB1 expression
quartiles and survival (both OS and PFS) was independent of the
treatment applied, suggesting a novel mechanism of molecular
pathogenesis of CLL, which is beyond control by the currently
available CLL treatment modalities. Targeting LaminB1-associated
mechanisms in CLL may provide another step towards the post-
chemotherapy era and complement existing therapies, potentially
gaining even larger therapeutic margins for this disease. As low
LMNB1 expression was strongly associated with clinically adverse
cytogenetic abnormalities, it is also tempting to speculate that,
due to its proximal role in the nuclear structure and function,
Lamin B1 may serve as a safeguard against chromosomal
aberrations during the clonal evolution of CLL.
Deletions of 13q and 11q represent the most frequent and co-
occurring aberrations in CLL25 and loss of the DLEU2/miR-15a/16-1
cluster on 13q14 in mice is sufﬁcient to initiate B-cell lymphopro-
liferative disorders with CLL-like phenotypes.44 Moreover, deletion
13q and trisomy 12, followed by deletion 11q, have been
identiﬁed as early drivers in the evolutionary process of CLL.45
Therefore, we hypothesise that the observed signiﬁcant drops in
Lamin B1 binding upon induction of SHM especially on chromo-
somes 13 and 12, or with slightly lesser extend on chromosome
11, may constitute the central selective vulnerability for deleter-
ious hits initiating the development of CLL.
In line with this suggestion, defects of Lamin B1 expression and
processing have previously been linked to aberrant interphase
chromosome positioning46 and chromatin instability47a poten-
tial path to chromosomal aberrations. However, a direct functional
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link between LMNB1 expression and chromosomal abnormalities
is yet to be established.
Here, we also show that nuclear Lamin B1 is decreased in the
majority of GC-derived lymphomas. Furthermore, sequential
biopsies from individuals with transformed FL showed a notice-
able decrease of perinuclear Lamin B1 content during FL
transformation. The latter, unlike in CD27+ memory B or mCLL
cells, suggests a GC-based clonal selection of Lamin B1low B cells
with their subsequent propagation into lymphoma cells, pre-
sumably due to increased mutational load associated with more
permissive chromatin state. From a translational perspective,
reduced levels of Lamin B1 in FL could be developed into a robust
molecular biomarker predicting transformation of indolent
lymphoma. At the moment, despite major advances in technol-
ogy, no biomarker other than histologic grade has proven to be
sufﬁciently robust to be widely accepted clinically.48
Overall, here we propose that Lamin B1 is an upstream
epigenetic regulator of SHM in GC B cells. Functionally, activation
of GC B cells is associated with a drop in Lamin B1 and release of
unrearranged IgV chromatin domains from the restrictive inﬂu-
ence of LADs, in turn, enabling normal SHM to occur. Finally, we
suggest that this permissive chromatin state also increases the
likelihood of off target hits that ultimately contribute to the
formation and progression of GC lymphomas and, at the post-GC
level, CLL. Figure 4e represents a principal schema, outlining the
Lamin B1 dynamics in normal and malignant B cells.
Having suggested a functional involvement of Lamin B1 in SHM
regulation and tumour progression, there is a number of
questions that are still outstanding and warrant further investiga-
tion. Firstly, it will be important to understand how Lamin B1 is
regulated within the GCs. Our data suggest that differential mRNA
expression could be one of these factors. However, given a rather
rapid reduction of Lamin B1 incorporation during SHM induction
in BL2 cells (in our system, as early as 90 min), one would suggest
that post-translational regulation, could be equally involved in the
reduction of nuclear Lamin B1. Within that context, it is possible
that Lamin B1 phosphorylation by cdk1 and protein kinase C49 is
one of the mechanisms for the rapid disassembly of nuclear Lamin
B1 in GC B cells. Next, as we were unable to identify DNA
methylation as a source for the differential LMNB1 expression in
CLL, establishing this mechanism would provide a novel insight
into the pathophysiology of this disease, with clear translational
potential.
Finally, taking into account clear involvement of Lamin B1 in the
pathophysiology of GC and post-GC B-cell malignancies, manip-
ulating nuclear Lamin B1 levels could provide a novel therapeutic
approach to these tumours, beyond the treatment modalities
based on chemotherapy or monoclonal antibodies. Within this
context, we believe that Lamin B1 phosphorylation and farnesyla-
tion would be the primary therapeutic targets to control the
dynamics of nuclear lamina in leukaemia and lymphoma.
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